Medicine and Surgery, University of Parma, Parma, Italy.
J Rehabil Med. 2021 Apr 27;53(4):jrm00182. doi: 10.2340/16501977-2817.
To conduct a systematic review of randomized controlled trials about the safety (number and severity of adverse events) and efficacy (pain reduction and functional improvement) of mesotherapy in musculoskeletal disorders, and to compare them with other therapeutic options, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement.
A search of PubMed, Cochrane Library and Scopus database resulted in an initial total of 16,253 records. A total of 931 articles were included in the study. A final total of 7 articles, published from 1 Jan 1999 until 30 Apr 2020 were selected. Two independent reviewers selected potentially relevant studies based on the inclusion criteria for full-text reading. They evaluated the methodological quality of each study and included only studies of high methodological quality, according to the Physiotherapy Evidence Database scale.
Seven studies were included in the meta-analysis, and visual analogue scale scores before and after mesotherapy were considered. A statistically significant reduction in visual analogue scale score in the mesotherapy group was reported in comparison with the control group in all except 1 of the trials. Mesotherapy was found to be a safe procedure with mild and temporary side-effects, such as nausea, fatigue, numbness, sweating, headache, ecchymosis, bleeding, pain and local reaction at the injection site.
Mesotherapy proved to be more effective than systemic therapy in the treatment of local pain and functional limitations caused by a variety of musculoskeletal conditions. However, because of the heterogeneity of the analysed studies in terms of injected drugs, administration technique, associated treatments, frequency and total number of sessions, more randomized controlled trials are needed, comparing a standardized mesotherapy protocol with a systemic treatments.
按照系统评价和荟萃分析的首选报告项目(PRISMA)声明,对肌肉骨骼疾病中中胚层疗法的安全性(不良事件的数量和严重程度)和疗效(疼痛减轻和功能改善)的随机对照试验进行系统评价,并与其他治疗选择进行比较。
在 PubMed、Cochrane 图书馆和 Scopus 数据库中进行检索,最初共得到 16253 条记录。共纳入 931 篇文章进行研究。最终共有 7 篇文章于 1999 年 1 月 1 日至 2020 年 4 月 30 日发表,被选中进行全文阅读。两名独立的审查员根据纳入标准选择了可能相关的研究。他们根据物理治疗证据数据库量表评估了每一项研究的方法学质量,并仅纳入了高质量的研究。
7 项研究被纳入荟萃分析,且考虑了中胚层疗法前后的视觉模拟量表评分。除了 1 项试验外,所有试验均报道中胚层疗法组的视觉模拟量表评分较对照组有统计学意义的降低。中胚层疗法被认为是一种安全的程序,其副作用轻微且短暂,如恶心、疲劳、麻木、出汗、头痛、瘀斑、出血、疼痛和注射部位局部反应。
中胚层疗法在治疗多种肌肉骨骼疾病引起的局部疼痛和功能障碍方面,比全身治疗更有效。然而,由于分析研究在注射药物、给药技术、相关治疗、频率和总疗程方面存在异质性,需要更多的随机对照试验,将标准化的中胚层疗法方案与全身治疗进行比较。